


# C49

## Analysis of Body Fluids in Clinical Chemistry



This guideline provides information for the medical laboratory for evaluating measurement procedures, as well as a strategy to characterize assay performance, when applied to body fluid matrixes. Key concepts that apply to the entire test cycle, including preexamination, examination, and postexamination phases of body fluid testing, are discussed.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: +1.610.688.0100  
F: +1.610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@cls.org](mailto:standard@cls.org)

---

## Analysis of Body Fluids in Clinical Chemistry

Deanna Franke, MT(ASCP), PhD, DABCC  
Darci R. Block, PhD, DABCC  
Alicia Algeciras-Schimmich, PhD, DABCC, FACB  
Richard J. Baltaro, MD, PhD, FCAP  
Marvin Berman, PhD  
Sutirtha Chakraborty, MD  
Idris Yahays Mohammed, MBBS, MSc, FMCPATH  
Marisa Needham, PhD, DABCC  
Robert Rej, PhD  
Kiang-Teck J. Yeo, PhD, DABCC, FAACC

### Abstract

Clinical and Laboratory Standards Institute guideline C49—*Analysis of Body Fluids in Clinical Chemistry* provides guidance to the medical laboratory for evaluating measurement procedures, as well as a strategy to characterize assay performance, when applied to body fluid matrixes. Key concepts that apply to the entire test cycle, including preexamination, examination, and postexamination phases of body fluid testing are discussed. This guideline does not consider serum, plasma, whole blood, or fluids for which measurement procedures typically have performance claims in the measurement procedure documentation. Appendix A provides didactic content on the anatomy, physiology, and pathophysiology of fluid accumulation. Appendix B provides the medical rationale for quantifying measurands in body fluids and the interpretation of results in the context of disease. Appendix C provides the user with a quick reference guide to the suggested utility of fluid and measurand combinations.

Clinical and Laboratory Standards Institute (CLSI). *Analysis of Body Fluids in Clinical Chemistry*. 2nd ed. CLSI guideline C49 (ISBN 978-1-68440-023-2 [Print]; ISBN 978-1-68440-024-9 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).

Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Analysis of Body Fluids in Clinical Chemistry*. 2nd ed. CLSI guideline C49. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

### **Previous Editions:**

June 2006, April 2007

ISBN 978-1-68440-023-2 (Print)  
ISBN 978-1-68440-024-9 (Electronic)  
ISSN 1558-6502 (Print)  
ISSN 2162-2914 (Electronic)

Volume 38, Number 20

## Committee Membership

### Consensus Council

**Dennis J. Ernst, MT(ASCP),  
NCPT(NCCT)  
Chairholder  
Center for Phlebotomy Education  
USA**

**Mary Lou Gantzer, PhD, FACB  
Vice-Chairholder  
USA**

J. Rex Astles, PhD, FACB, DABCC  
Centers for Disease Control and  
Prevention  
USA

Lucia M. Berte, MA, MT(ASCP)SBB,  
DLM, CQA(ASQ)CMQ/OE  
Laboratories Made Better!  
USA

Karen W. Dyer, MT(ASCP), DLM  
Centers for Medicare & Medicaid  
Services  
USA

Thomas R. Fritsche, MD, PhD, FCAP,  
FIDSA  
Marshfield Clinic  
USA

Loralie J. Langman, PhD, DABCC,  
FACB, F-ABFT  
Mayo Clinic  
USA

James R. Petisce, PhD  
BD Diagnostic Systems  
USA

Andrew Quintenz  
Bio-Rad Laboratories, Inc.  
USA

Robert Rej, PhD  
New York State Department of  
Health – Wadsworth Center  
USA

Zivana Tezak, PhD  
FDA Center for Devices and  
Radiological Health  
USA

### Document Development Committee on Analysis of Body Fluids in Clinical Chemistry

**Deanna Franke, MT(ASCP), PhD,  
DABCC  
Chairholder  
Carolinas HealthCare System  
USA**

**Darci R. Block, PhD, DABCC  
Vice-Chairholder  
Mayo Clinic  
USA**

Richard J. Baltaro, MD, PhD, FCAP  
East Carolina University  
USA

Marvin Berman, PhD  
Abbott Laboratories,  
Abbott Diagnostics Division  
USA

Patrice Donovan, MT  
Schneider Regional Medical Center  
USA

Andrea Griesmacher, MD  
University Hospital Innsbruck  
Austria

James F. Pierson-Perry  
Siemens Healthcare Diagnostics Inc.  
USA

Robert Rej, PhD  
New York State Department of Health –  
Wadsworth Center  
USA

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Luann Ochs, MS  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Catherine E.M. Jenkins  
*Editor*

Kristy L. Leirer, MS  
*Editor*

Laura Martin  
*Editor*

## Acknowledgment for the Expert Panel on Clinical Chemistry and Toxicology

CLSI, the Consensus Council, and the Document Development Committee on Analysis of Body Fluids in Clinical Chemistry gratefully acknowledge the Expert Panel on Clinical Chemistry and Toxicology for serving as technical advisors and subject matter experts during the development of this guideline.

**Johanna Camara, PhD**  
**Chairholder**  
**National Institute of Standards and Technology**  
 USA

**Lorin M. Bachmann, PhD, DABCC**  
**Vice-Chairholder**  
**Virginia Commonwealth University Health System**  
 USA

Karl De Vore  
 Bio-Rad Laboratories, Inc.  
 USA

Lili Duan, PhD  
 FDA Center for Devices and Radiological Health  
 USA

Kamisha Johnson-Davis, PhD, DABCC, FACB  
 University of Utah and ARUP Laboratories  
 USA

Gregory T. Maine, PhD, FACB  
 Abbott  
 USA

Godwin Ogbonna, PhD  
 Ortho-Clinical Diagnostics, Inc.  
 USA

Curtis Oleschuk, PhD, FCACB  
 Diagnostic Services of Manitoba  
 Canada

David B. Sacks, MB, ChB, FRCPath  
 National Institutes of Health  
 USA

## Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Analysis of Body Fluids in Clinical Chemistry gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Charbel Abou-Diwan, PhD, DABCC, FACB  
 Banner Good Samaritan Regional Medical Center  
 USA

Alicia Algeciras-Schimmich, PhD, DABCC, FACB  
 Mayo Foundation  
 USA

Sutirtha Chakraborty, MD  
 Peerless Hospital & B.K. Roy Research Center  
 India

James J. Miller, PhD, DABCC, FACB  
 University of Louisville Hospital  
 USA

Idris Yahays Mohammed, MBBS, MSc, FMCPATH  
 Bayero University  
 Nigeria

Marisa Needham, PhD, DABCC  
 Duke University Medical Center  
 USA

Wadid Sadek, PharmD, MS, PhD  
 USA

Kiang-Teck J. Yeo, PhD, DABCC, FAACC  
 University of Chicago  
 USA

Michael Yu, MBA, MLS(ASCP)  
 Kaiser Permanente Panorama City Hospital  
 USA

## Contents

Abstract .....	i
Committee Membership.....	iii
Foreword.....	vii
Chapter 1: Introduction .....	1
1.1 Scope.....	1
1.2 Standard Precautions.....	1
1.3 Terminology.....	1
Chapter 2: Key Validation Studies for Body Fluids .....	5
Chapter 3: Preexamination Considerations.....	7
3.1 Clinical Requests .....	7
3.2 Specimen Collection and Transport.....	7
3.3 Specimen Processing .....	9
Chapter 4: Examination Considerations .....	11
4.1 Matrix Effects on Medical Laboratory Measurements .....	11
4.2 Measurement Procedure Selection for Validating Body Fluids.....	12
Chapter 5: Measurement Procedure Validation .....	13
5.1 Accuracy .....	13
5.2 Precision.....	17
5.3 Detection Capability .....	18
5.4 Linearity, Measuring, and Reportable Intervals.....	18
5.5 Reference Interval and Medical Decision Limits .....	21
5.6 Interferences and Selectivity.....	22
5.7 Stability.....	25
Chapter 6: Results Reporting and Interpretation.....	27
Chapter 7: Ongoing Quality Assurance .....	29
7.1 Quality Control Selection .....	29
7.2 New Reagent Lot Validation: Measurement Procedure Reagents and Calibrators.....	29
7.3 Biannual Instrument and Measurement Procedure Comparisons .....	29
7.4 Biannual Linearity and Reportable Interval Verification .....	29
7.5 External Quality Assessment .....	30
Chapter 8: Conclusion.....	32
Chapter 9: Supplemental Information.....	32
References.....	33
Appendix A. Composition and Pathogenesis of Body Fluids.....	36
Appendix B. Clinically Significant Measurands in Body Fluids.....	54
Appendix C. Fluid and Measurand Combinations: Quick Reference Guide .....	78
The Quality Management System Approach .....	80
Related CLSI Reference Materials .....	82



## Foreword

Since C49's original publication, regulatory requirements for laboratories performing body fluid testing have changed. In addition, the number of publications in peer-reviewed journals as well as single case studies documenting the diagnostic need to test a number of measurands in body fluids has increased substantially. To comply with regulatory requirements when choosing to offer body fluid testing, medical laboratories should determine which fluid types are appropriate to accept for testing through collaborating with the requesting clinical areas, characterizing measurement procedure suitability, and understanding performance limitations of methods not designated for use on body fluids by *in vitro* diagnostics manufacturers. This information is critical to ensure the accuracy of reported results, because physicians use these data for patient management.

## Overview of Changes

This guideline replaces the previous edition of the approved guideline, C49-A, published in April 2007. This second edition of C49 provides medical laboratories with a strategy to evaluate method performance, as well as guidance on which measurands have clinical relevance when measured in body fluid matrixes. Several changes were made in this edition, including:

- Providing medical laboratories with a workflow that:
  - Outlines important preexamination conditions to consider when validating and performing body fluid testing (see Chapter 3)
  - Discusses key concepts for body fluid matrix considerations and measurement procedure selection (see Chapter 4)
  - Offers strategies for developing a measurement procedure validation plan to provide meaningful and accurate results for appropriate and timely patient management (see Chapter 5)
  - Offers recommendations for reporting body fluid tests to aid in the diagnostic interpretation of results (see Chapter 6)
  - Covers general laboratory QA activities to support ongoing body fluid testing (see Chapter 7)
- Assisting laboratories in minimizing patient risk and maximizing diagnostic return by:
  - Providing general information related to body fluid composition and pathogenic processes that lead to accumulation of body fluids (see Appendix A)
  - Defining the measurands and their expected concentrations that have diagnostic utility when measured in body fluids (see Appendix B)

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

## Key Words

Body fluid, exudate, matrix effect, measurement procedure validation, organ injury, serous fluid, synovial fluid, transudate



# Analysis of Body Fluids in Clinical Chemistry

## Chapter 1: Introduction

This chapter includes:

- Guideline’s scope and applicable exclusions
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the guideline
- Abbreviations and acronyms used in the guideline

### 1.1 Scope

C49 provides guidance to medical laboratories for the appropriate application of measurement procedures for body fluid testing and for reporting results. This guideline primarily focuses on the recommended practice for verification of measurement procedures for measurands in body fluids and is applicable for laboratory testing requests on body fluids that do not have performance claims in the manufacturer’s package insert or an equivalent validated laboratory-developed test. C49 does not cover serum, plasma, whole blood, urine, or fluids (eg, CSF) for which measurement procedures typically have performance claims in the manufacturer’s package insert.

### 1.2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.<sup>1</sup> For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.<sup>2</sup>

### 1.3 Terminology

#### 1.3.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process